Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-? monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Afelimomab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Afelimomab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Afelimomab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Afelimomab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Afelimomab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Afelimomab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Afelimomab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Afelimomab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Afelimomab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Afelimomab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Afelimomab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Afelimomab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Afelimomab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Afelimomab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Afelimomab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Afelimomab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Afelimomab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Afelimomab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Afelimomab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Afelimomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Afelimomab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Afelimomab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Afelimomab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Afelimomab. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Afelimomab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Afelimomab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Afelimomab. |
| Cladribine | Afelimomab may increase the immunosuppressive activities of Cladribine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Afelimomab. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Afelimomab. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Afelimomab. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Afelimomab. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Afelimomab. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Afelimomab. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Afelimomab. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Afelimomab. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Afelimomab. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Afelimomab. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Afelimomab. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Afelimomab. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Afelimomab. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Afelimomab. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Afelimomab. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Afelimomab. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Afelimomab. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Afelimomab. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Afelimomab. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Afelimomab. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Afelimomab. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Afelimomab. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Afelimomab. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Afelimomab. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Afelimomab. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Afelimomab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Afelimomab. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Afelimomab. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Afelimomab. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Afelimomab. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Afelimomab. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Afelimomab. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Afelimomab. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Afelimomab. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Afelimomab. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Afelimomab. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Afelimomab. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Afelimomab. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Afelimomab. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Afelimomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Afelimomab. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Afelimomab. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Afelimomab. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Afelimomab. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Afelimomab. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Afelimomab. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Afelimomab. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Afelimomab. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Afelimomab is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Afelimomab is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Afelimomab is combined with Human interferon omega-1. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Afelimomab is combined with Abetimus. |
| Golimumab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Golimumab. |
| Belatacept | The risk or severity of adverse effects can be increased when Afelimomab is combined with Belatacept. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Afelimomab is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Afelimomab is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Afelimomab is combined with Eribulin. |
| Belimumab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Belimumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Afelimomab is combined with Teriflunomide. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Afelimomab is combined with Carfilzomib. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Afelimomab is combined with Dimethyl fumarate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Obinutuzumab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Secukinumab. |
| Siltuximab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Siltuximab. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Blinatumomab. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Dinutuximab. |
| Tixocortol | The risk or severity of adverse effects can be increased when Afelimomab is combined with Tixocortol. |
| Peginterferon beta-1a | The risk or severity of adverse effects can be increased when Afelimomab is combined with Peginterferon beta-1a. |
| Antilymphocyte immunoglobulin (horse) | The risk or severity of adverse effects can be increased when Afelimomab is combined with Antilymphocyte immunoglobulin (horse). |
| Tepoxalin | The risk or severity of adverse effects can be increased when Afelimomab is combined with Tepoxalin. |